AstraZeneca PLC (STO:AZN)
Sweden
· Delayed Price · Currency is SEK | Market Cap | 2.40T |
| Revenue (ttm) | 598.44B |
| Net Income (ttm) | 77.86B |
| Shares Out | n/a |
| EPS (ttm) | 49.80 |
| PE Ratio | 30.78 |
| Forward PE | n/a |
| Dividend | 33.75 (2.15%) |
| Ex-Dividend Date | Feb 20, 2025 |
| Volume | 276,305 |
| Average Volume | 311,136 |
| Open | 1,560.00 |
| Previous Close | 1,572.00 |
| Day's Range | 1,529.50 - 1,560.50 |
| 52-Week Range | 1,360.00 - 1,799.00 |
| Beta | 0.16 |
| RSI | 44.15 |
| Earnings Date | Apr 29, 2025 |
About AstraZeneca
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacturing, and commercialization of prescription medicines. Its marketed products include Calquence, Enhertu, Faslodex, Imfinzi, Iressa, Koselugo, Lumoxiti, Lynparza, Orpathys, Tagrisso, and Zoladex for oncology; Brilinta/Brilique, Bydureon/Byetta, BCise, Byetta, Crestor, Evrenzo, Farxiga/Forxiga, Komboglyze/Kombiglyze XR, Lokelma, Onglyza, Qtern, and Xigduo/Xigduo XR for cardiovascular, renal, and metabolism diseases; Bevespi Aerosphere, Breztri Aerosphere... [Read more]
Financial Performance
In 2024, AstraZeneca's revenue was $54.07 billion, an increase of 18.03% compared to the previous year's $45.81 billion. Earnings were $7.04 billion, an increase of 18.14%.
Financial numbers in USD Financial StatementsNews
AstraZeneca meets main goal in late stage gastric cancer treatment trial
AstraZeneca's gastric cancer treatment, IMFINZI, demonstrated a statistically significant improvement in the primary endpoint. Read more here.
AstraZeneca's Imfinzi-Based Regimen Shows Improved Event-Free Survival In Early-Stage Gastric Cancer Patients
On Friday, AstraZeneca Plc (NASDAQ: AZN) released high-level results from the MATTERHORN Phase 3 trial evaluating Imfinzi (durvalumab) as a perioperative treatment for patients with resectable Stage ...
AstraZeneca receives approval to import Lokelma for hyperkalaemia treatment in India
AstraZeneca Pharma India Limited has received regulatory approval from the Central Drugs Standard Control Organisation (CDSCO), Directorate General of Health Services, Government of India, to import a...
6 Ideal Buys From 14 'Safer' March Dividends On Bloomberg 2025 Watch List Of 50
Bloomberg Intelligence analysts identified 50 stocks for 2025, focusing on catalysts like new leadership, acquisitions, and AI advancements, with 35 paying dividends. 14 of these dividend-paying stock...
AstraZeneca: A Big Pharma Blue Chip To Buy Now
AstraZeneca boasts a remarkably healthy drug portfolio and a pipeline of promising drugs in clinical development. Read why AZN stock is a Buy.
/C O R R E C T I O N -- Compugen Ltd./
In the news release, Compugen Reports Fourth Quarter and Full Year 2024 Results, issued 04-Mar-2025 by Compugen Ltd. over PR Newswire, in the Conference Call and Webcast Information section, the link ...
2025 Endothelin Receptor Antagonist Pipeline Insights for 10+ Companies and 15+ Pipeline Drugs, Including Zibotentan (AstraZeneca), SC0062 (Biocity Biopharmaceutics), and GMA301 (Gmax Biopharm)
Dublin, March 04, 2025 (GLOBE NEWSWIRE) -- The "Endothelin Receptor Antagonist - Pipeline Insight, 2025" clinical trials has been added to ResearchAndMarkets.com's offering.
Daiichi Sankyo and AstraZeneca report positive result in trial for its gastric cancer treatment
ENHERTU® Demonstrated Statistically Significant and Clinically Meaningful Improvement in Overall Survival in Patients with HER2 Positive Metastatic Gastric Cancer at Interim Analysis of DESTINY-Gastric04 Phase 3 Trial
Phase 3 results confirm the efficacy of Daiichi Sankyo and AstraZeneca's ENHERTU in second-line metastatic gastric cancer DESTINY-Gastric04 will be unblinded at interim analysis based on the superior ...
ENHERTU® Demonstrated Statistically Significant and Clinically Meaningful Improvement in Overall Survival in Patients with HER2 Positive Metastatic Gastric Cancer at Interim Analysis of DESTINY-Gastric04 Phase 3 Trial
TOKYO & BASKING RIDGE, N.J.--(BUSINESS WIRE)--ENHERTU Demonstrated Statistically Significant and Clinically Meaningful Improvement in Overall Survival in HER2+ Metastatic Gastric Cancer.
Stocks to watch today: AstraZeneca, Glenmark, Aurobindo Pharma, Mankind Pharma, Bayer Crop in pharma updates
The pharmaceutical sector saw a mix of regulatory approvals and tax-related issues. Key Highlights AstraZeneca: Received approval from the Central Drugs Standard Control Organisation to import a lung ...
AstraZeneca's TEZSPIRE Shows Promising Results in Phase III WAYPOINT Trial for Nasal Polyps
AstraZeneca's TEZSPIRE Shows Promising Results in Phase III WAYPOINT Trial for Nasal Polyps
POSITIVE RESULTS FROM TEZSPIRE® (TEZEPELUMAB-EKKO) PHASE 3 WAYPOINT TRIAL HIGHLIGHT RAPID, SUSTAINED EFFECT IN CHRONIC RHINOSINUSITIS WITH NASAL POLYPS
Significantly Reduced Nasal Congestion, Polyp Size and Nearly Eliminated Need for Surgery Data Published in NEJM and Presented at AAAAI/WAO 2025 THOUSAND OAKS, Calif. , March 1, 2025 /PRNewswire/ -- A...
Positive results from the TEZSPIRE Phase III WAYPOINT trial highlight rapid and sustained effect in chronic rhinosinusitis with nasal polyps
TEZSPIRE significantly reduced nasal congestion, polyp size and nearly eliminated the need for surgery in patients with chronic rhinosinusitis with nasal polyps WAYPOINT data published in New England ...
Positive results from the TEZSPIRE Phase III WAYPOINT trial highlight rapid and sustained effect in chronic rhinosinusitis with nasal polyps
WILMINGTON, Del.--(BUSINESS WIRE)--Full results from the positive Phase III WAYPOINT trial showed AstraZeneca and Amgen's TEZSPIRE® (tezepelumab-ekko) significantly reduced nasal polyp severity, the n...
AstraZeneca's metastatic breast cancer treatment gets EU recommendation
AstraZeneca and Daiichi Sankyo said on Friday that the European Medicines Agency endorsed ENHERTU for the treatment of metastatic breast cancer.
EU backs AstraZeneca, Daiichi's Enhertu for breast cancer treatment post endocrine therapy
The European Union's health regulator on Friday backed AstraZeneca and Daiichi Sankyo's drug Enhertu as a breast cancer treatment for patients who received endocrine therapy but are not suitable for a...
Neurofibromatoses Therapeutics Competitive Landscape Report 2024: Pipeline Holds 35 Molecules - Currently Only 1 Approved Innovator Drug, AstraZeneca's (Koselugo/Coselugo) Selumetinib Sulfate
Dublin, Feb. 28, 2025 (GLOBE NEWSWIRE) -- The "Neurofibromatoses: Competitive Landscape" report has been added to ResearchAndMarkets.com's offering. This reports provides a data-driven overview of the...
BioInvent International AB: Year-End Report January 1 - December 31, 2024
LUND, SWEDEN / ACCESS Newswire / February 27, 2025 / BioInvent International (STO:BINV) "2024 was a year with several exciting developments reported from across our broad portfolio of clinical program...
AstraZeneca’s camizestrant showed improvement in breast cancer treatment during late stage trial
Camizestrant demonstrated highly statistically significant and clinically meaningful improvement in progression-free survival in 1st-line advanced HR-positive breast cancer with an emergent ESR1 tumor mutation in SERENA-6 Phase III trial
WILMINGTON, Del.--(BUSINESS WIRE)--Positive high-level results from a planned interim analysis of the SERENA-6 Phase III trial showed that AstraZeneca's camizestrant in combination with a cyclin-depen...
AstraZeneca therapy improves survival in late-stage breast cancer trial
Pharmaceuticals major AstraZeneca said on Wednesday that its experimental treatment, camizestrant, improved survival in patients with an advanced form of breast cancer without the disease getting wors...
Final Trades: Starbucks, Astrazeneca, Western Union and the IYR
The Investment Committee give you their top stocks to watch for the second half.
Final Trades: Starbucks, Astrazeneca, Western Union and the IYR
The Investment Committee give you their top stocks to watch for the second half.
Jamie Murray's Past Picks: 3i Group ADR, AstraZeneca & Manulife
Jamie Murray, portfolio manager and head of research at the Murray Wealth Group, discusses his past stock picks and how they're doing in the market today.